Prophylactic FXI inhibition has been predicted to be beneficial in VTE, thrombosis in end-stage renal disease, and for anticoagulation in patients undergoing extracorporeal membrane oxygenation or hemodialysis. This evidence concerns the gene F11 and chronic kidney disease.